News

Hosted on MSN1mon
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...
Yahoo Finance17d
FDA Approves Johnson & Johnson’s IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA ... more about this approval in Johnson & Johnson’s news ...
Medscape13d
FDA Okays Dihydroergotamine Nasal Spray for Acute Migraine
The US Food and Drug Administration (FDA) has approved dihydroergotamine (DHE) nasal powder (Atzumi, Satsuma Pharmaceuticals Inc) for the acute treatment of migraine with or without aura in adults ...
Mint17d
US FDA approves Johnson & Johnson's drug for immune-mediated disorder
Health care giantJohnson & Johnson said on Wednesday the US Food and Drug Administration (FDA) has approved its drug to treat patients aged 12 years and older with an immune-mediated disorder.
Yahoo Finance1mon
FDA approves Neurelis’ nasal spray for seizures
The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters ...
Nasdaq17d
Johnson & Johnson Announces FDA Approval Of IMAAVY
(RTTNews) - Johnson & Johnson (JNJ) announced the FDA has approved IMAAVY, a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis. The approval is supported ...
manilatimes17d
FDA Approves Johnson & Johnson's IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY ... Learn more about this approval in Johnson ...
Yahoo Finance17d
FDA Approves Johnson & Johnson’s IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY ... Learn more about this approval in Johnson ...